Intensity Therapeutics, known by the stock symbol INTS, saw its shares surge by 128.6% in premarket trading, reaching $0.62. This remarkable increase is attributed to promising results from a recent clinical trial of its experimental cancer drug, INT230-6.
Encouraging Clinical Trial Results
The study, published in the reputable journal Lancet’s eBioMedicine, highlighted the effectiveness of INT230-6 in patients with advanced cancers. According to the findings, the drug achieved a disease control rate of 75% among participants.
Direct Tumor Injection with Positive Outcomes
One of the notable aspects of INT230-6 is its method of administration. The drug is injected directly into tumors, which was shown to have additional benefits. Specifically, 20% of patients experienced a reduction in untreated tumors, suggesting a broader anti-cancer effect.
Survival Rates and Patient Outcomes
In terms of survival rates, the median survival for patients receiving INT230-6 was recorded at 11.9 months. For sarcoma patients specifically, survival rates improved significantly, rising to 21.3 months.
Stock Performance Trends
- INTS shares rose 128.6% to $0.62 premarket.
- 75% disease control rate in advanced cancer patients.
- 20% of patients saw untreated tumors shrink.
- Median survival was 11.9 months; 21.3 months for sarcoma patients.
- Stock was down approximately 85% year-to-date before this announcement.
The impressive trial results have rejuvenated interest in Intensity Therapeutics, providing a much-needed boost to the company’s stock performance. As research progresses, the potential applications of INT230-6 may pave the way for new treatment options in cancer therapy.
